

AD-A050 538

ARMY RESEARCH INST OF ENVIRONMENTAL MEDICINE NATICK MASS F/G 6/5  
MORPHINE DEPRESSION OF VENTILATORY RESPONSE TO HYPOXIA, AND REV--ETC(U)  
JAN 77 R B WEISKOPF, G VOLPE, V FORTE

UNCLASSIFIED

USARIEM-M-8/77


NL

1 OF 1  
AD  
A050538



END  
DATE  
FILMED  
3-78  
DDC

AD A 050538

AD No. 

MORPHINE DEPRESSION OF VENTILATORY RESPONSE TO HYPOXIA,  
AND REVERSAL BY NALOXONE

Richard B. Weiskopf, MD, MAJ, MC\*  
George Volpe, BS  
Vincent Forte, BA  
Nancy McGavock, BS

US Army Research Institute  
of Environmental Medicine  
Natick, MA 01760

\*Present address:

Letterman Army Institute of Research  
Presidio of San Francisco, CA 94129

Presented, in part, at the annual meeting of the American  
Society of Anesthesiologists, San Francisco, California,  
October 1976.

**DISTRIBUTION STATEMENT - A**  
Approved for public release  
Distribution Unlimited

Abbreviated Title:

Morphine, Naloxone, and Hypoxic Ventilation

ADDITIONAL FOR		
NTIS	White Section	<input checked="checked" type="checkbox"/>
USC	Half Section	<input type="checkbox"/>
UNANNOUNCED		<input type="checkbox"/>
JUSTIFICATION		
BY		
DISTINCTION/AVAILABILITY CODES		
DIWL	AVAIL. CODE/NO. OF COPIES	
A		



**Key Words:**

Regulation of respiration; "isocapnic" hypoxia;  
ventilation; narcotics: morphine; narcotic antagonists:  
naloxone



Abstract .

Ventilatory response to 'isocapnic' hypoxia was measured in awake beagle dogs prior to and following administration of intravenous morphine sulfate, 0.6 mg/kg. Hypoxic ventilation was depressed within 30 minutes, was maximally depressed at one to two hours, and remained depressed for at least six to seven hours following the administration of morphine. Naloxone, 0.4 mg IV, completely reversed the morphine depression of the ventilatory response to hypoxia, but only transiently; 30 to 45 minutes after naloxone reversal, the ventilatory response to hypoxia was again significantly depressed. Naloxone alone demonstrated mild agonist properties on the ventilatory response to hypoxia, but the effect varied among the dogs.

Evidence accumulated during the past 25 years clearly documents that anesthetic agents,<sup>1-4</sup> including morphine,<sup>5,6</sup> depress the ventilatory response to carbon dioxide. However, it has been only in the past few years that the effect of an anesthetic agent (halothane) on the ventilatory response to hypoxia was first tested<sup>7,8</sup> and shown to cause significant depression. More recently, enflurane, barbiturates, and subcutaneous morphine sulfate have also been shown to depress the ventilatory response to hypoxia.<sup>9-11</sup>

Since anesthesiologists frequently use intravenous morphine in the immediate postoperative period, when respiratory control is of major concern, we sought to examine the effect of small doses of intravenous morphine on the ventilatory response to hypoxia, delineate the time-course of the effect, and determine the efficacy of a narcotic antagonist in reversing the effect.



### Methods:

Three beagle dogs (weight range 9.3-13.1 kg) were provided with permanent tracheostomies, which were allowed to completely heal prior to the initiation of these studies. A minimum of two days elapsed prior to restudying an animal. No dog was studied more frequently than twice in one week.

The ventilatory response to rapidly progressive "isocapnic" hypoxia was measured in each dog, on each experimental day, in the awake, unmedicated condition. Complete details of the method of ventilatory testing have been published elsewhere<sup>12,13</sup>; however, a brief description follows. With the dog breathing through a cuffed tracheostomy tube in a closed-circle system, after establishing a resting, mildly hyperoxic (end-tidal  $P_{O_2}$ ,  $P_{ET}O_2 = 200$  torr) steady state,  $P_{ET}O_2$  was progressively reduced to 40 torr during a five minute period, while  $P_{ET}CO_2$  was held constant at 40 torr by variable bypass of a  $CO_2$  absorber.  $P_{O_2}$  and  $P_{CO_2}$  were continuously measured in the tracheostomy tube by mass spectrometry (Perkin-Elmer MGA 1100A)<sup>14</sup> with end-tidal values determined by an on-line digital computer (PDP 11/40) and displayed on a polygraph (Brush 200). Ventilation was measured by a Wedge Spirometer (Model 570, Med-Science Electronics, Inc.) attached to the closed-circle system by a bag-in-box, with breath-by-breath minute ventilation calculated by the on-line digital computer and displayed on the polygraph. Real-time plots of ventilation versus  $P_{ET}O_2$  were displayed on a Hewlett-Packard Model 7045A X-Y recorder.



Three separate series of drug studies were conducted:

1. Time-course of effect of morphine on ventilatory response to hypoxia: two of the dogs were utilized in this series; both were tested three times each. Following determination of the unmedicated ventilatory response to rapidly progressive "isocapnic" hypoxia, morphine sulfate, 0.6 mg/kg was administered intravenously, through a previously established intravenous route. This dose of morphine produced very mild sedation in these dogs. The evaluation of the ventilatory response to hypoxia was repeated several times during the succeeding six hours.

2. Reversibility of morphine effect by naloxone: all three dogs were tested three times each in this series. After determining the unmedicated ventilatory response to rapidly progressive "isocapnic" hypoxia, morphine sulfate 0.6 mg/kg was administered intravenously through a previously established intravenous route. Forty-five minutes later, the ventilatory response to rapidly progressive "isocapnic" hypoxia was again measured. With the animal maintained at  $P_{ET}O_2$  40 torr,  $P_{ET}CO_2$  40 torr, naloxone 0.4 mg was administered intravenously, while ventilation was continuously measured. Several minutes later, the dog was returned to the normoxic condition. Thirty to forty-five minutes thereafter, the ventilatory response to rapidly progressive "isocapnic" hypoxia was again measured. The ventilatory responses among these conditions were analyzed by a factorial analysis of variance and differences between individual means were tested at the 5% level using the Least Significant Difference Criteria.<sup>15</sup>

3. Effect of naloxone on ventilatory response to hypoxia:  
all three dogs were tested three times each in this series. The ventilatory response to rapidly progressive "isocapnic" hypoxia was measured in the awake, unmedicated condition, as above. With the animal maintained at  $P_{ET}O_2$  40 torr,  $P_{ET}CO_2$  40 torr, naloxone 0.4 mg was administered intravenously, while breath-by-breath ventilation was continuously measured. Ventilation before and after the administration of naloxone was compared by use of Student's paired t-test.

## Results:

### Time course of effect of morphine on ventilatory response to hypoxia:

In Figure 1 is plotted the time course of the effect of morphine on the ventilatory response to hypoxia in one dog. Each point indicates the mean ( $\pm$ SE) of three trials. The ventilatory response was depressed within 30 minutes (earliest test) after the intravenous administration. Depression was greatest (lowest ventilatory response) one to two hours following the administration of morphine, after which the response gradually increased. Six to seven hours following administration of morphine, the ventilatory response to hypoxia had recovered to approximately 70-80% of the unmedicated values.

### Reversibility of morphine effect by naloxone:

Table 1 compares for each dog, the mean ( $\pm$ SE) of three ventilatory responses to rapidly progressive "isocapnic" hypoxia in the unmedicated state with the three responses after morphine and the three responses after reversal with naloxone. All three dogs showed a statistically significant depression of the response 45 minutes after the intravenous administration of morphine. All three dogs exhibited a statistically significant increase in the ventilatory response three to four minutes after the administration of naloxone. The ventilatory response after reversal with naloxone was significantly greater than the unmedicated



response in two of the three dogs. Thirty to forty-five minutes after the administration of naloxone, however, the ventilatory response to hypoxia was significantly less than the response three to four minutes after naloxone administration in all three dogs, less than the unmedicated response, and greater than the response after morphine alone (statistically significant in two of the dogs).

#### Effect of naloxone on ventilatory response to hypoxia:

The three dogs differed in their responses to naloxone alone. Naloxone decreased the mean ( $\pm$ SE) ventilatory response to hypoxia of BJ ( $24.8 \pm 1.0$  to  $21.3 \pm 0.6$  L $\cdot$ min $^{-1}$ , BTPS;  $P < 0.05$ ), increased the response of JQ ( $19.3 \pm 2.0$  to  $23.0 \pm 1.4$  L $\cdot$ min $^{-1}$ , BTPS;  $P < 0.05$ ) and produced a statistically insignificant change in the response of PL ( $25.2 \pm 6.0$  to  $22.6 \pm 4.4$  L $\cdot$ min $^{-1}$ , BTPS;  $P > 0.2$ ).

### Discussion:

The plasma half-life of free morphine in man during the first six hours after administration is two to three hours,<sup>16,17</sup> with small amounts remaining detectable in the plasma for 48 hours.

The analgesic effect time-course approximates the time-course of plasma concentration of morphine.<sup>18,19</sup> If the disposition of morphine in dogs is similar to that in man, it is not surprising that we were able to detect a depression of the ventilatory response to hypoxia during the entire six hour duration of our experiments.

The ventilatory response was depressed to the greatest extent one to two hours following the intravenous administration of morphine. Weil, et al<sup>9</sup> also found a depressed response, greater at 60-90 minutes than at 15-30 minutes, after a subcutaneous dose of morphine; however, they did not continue their studies for longer than 90 minutes.

Naloxone, except in extremely high doses, is reported to be devoid of all narcotic agonist properties, including effects on ventilation.<sup>20-22</sup> However, this conclusion is based upon measurements made during unstimulated ventilation: a condition where a large variation exists around a relatively small ventilation. Jasinski, et al<sup>21</sup> failed to find a significant alteration by naloxone of a one point ventilatory response to carbon dioxide. We were able to elucidate an agonist effect of naloxone by investigating its effect on a respiratory system driven to a high degree of activity,

with a small variation around a relatively large ventilation. The agonist effect was variable among the three animals; stimulant in one, depressant in another, and no effect in the third. Alternatively, it is possible that naloxone alters the ventilatory response to hypoxia, but not to carbon dioxide. We did not test its effect on the latter. We have no information as to the agonist site of action: direct chemoreceptor, direct central, or indirect central, by alteration of cerebral blood flow.

Naloxone was completely effective in reversing the morphine depression of ventilatory response to hypoxia. Unfortunately, the reversal was relatively short-lived; 30-45 minutes after reversal, in two of the three dogs, more than 70% of the effect of the reversal had been lost. This length of action of naloxone is shorter than others have reported. Jasinski, et al<sup>23</sup> found naloxone to be an effective prophylactic of morphine action for at least nine hours. Palminteri states that a single dose of naloxone, in dogs, is an effective reversal agent for one to two hours.<sup>24</sup>

Perhaps the most interesting aspect of these studies is the finding that naloxone reversal, acutely, results in a ventilatory response to "isocapnic" hypoxia, which is greater than the unmedicated control response.



Resting ventilation, after narcotic reversal, is sometimes greater than ventilation measured prior to administration of narcotic.<sup>20</sup> This has been attributed to an accumulation of  $\text{CO}_2$  centrally, secondary to the rise in arterial  $\text{P}_{\text{CO}_2}$  as a result of the narcotic depressed ventilation.<sup>20</sup> This hypothesis does not explain our data because we maintained peripheral  $\text{P}_{\text{CO}_2}$  constant.

Several other explanations are possible<sup>20</sup>: (1) the narcotic antagonist has a direct respiratory stimulant activity; (2) the narcotic analgesic has both respiratory stimulant and depressant actions, and the antagonist selectively antagonizes the latter; (3) acute physical dependence is induced by the narcotic, shifting the sensitivity of the respiratory control system. Our evidence suggests that if (1) were true, the effect is mild and variable, and not sufficient to account for the consistent "rebound" effect seen in these dogs. We have no evidence regarding (2) or (3).

We offer an alternative hypothesis. If morphine decreases the cerebral vascular response to hypoxia, as has been also recently suggested by Chapman, et al,<sup>24</sup> central  $\text{P}_{\text{CO}_2}$  will be higher than during hypoxia without morphine, despite a similar arterial  $\text{P}_{\text{CO}_2}$ .<sup>13</sup> When the narcotic is reversed, there will be a central acidic stimulus greater than that which existed in the unmedicated hypoxic state. Even if cerebral blood flow were returned to the usual hypoxic value within seconds of reversal, it would be several minutes before

central  $P_{CO_2}$  approached the new steady-state value because of the two minute wash-out time of cerebral tissue.<sup>13,26</sup>

Although we can not directly translate these findings to man, the possibility exists that relatively small doses of morphine may markedly depress the usual increase in ventilation in response to hypoxia, and that although naloxone is capable of reversing the narcotic effect, the reversal may be of short duration.



## REFERENCES

1. Severinghaus JW, CP Larson, Jr.  
Respiration in anesthesia, in Handbook of Physiology, Section 3.  
Respiration, vol II, chap 49. Am Physiol Soc, Washington, DC,  
1965.
2. Munson ES, CP Larson, Jr., AA Babad, et al.  
The effects of halothane, fluroxene and cyclopropane on ventilation:  
A comparative study in man. Anesthesiology 27: 716-728,  
1966.
3. Larson CP, Jr., EI Eger II, M Maullem, et al.  
The effects of diethyl ether and methoxyflurane on ventilation.  
II. A comparative study in man. Anesthesiology 30: 174184,  
1969.
4. Fourcade HE, WC Stevens, CP Larson, Jr., et al.  
The ventilatory effects of Forane, a new inhaled anesthetic.  
Anesthesiology 35: 26-31, 1971.
5. Prescott F, SG Ransom, RH Thorp, et al.  
Effect of analgesics on respiratory response to carbon dioxide  
in man. Lancet 1: 340-344, 1949.
6. Eckenhoff JE, SR Oech.  
The effects of narcotics and antagonists upon respiration and  
circulation in man. Clin Pharmacol Ther 1: 483-524, 1960.
7. Raymond LW, RB Weiskopf, FJ Wright, et al.  
Respiratory response to hypoxia and CO<sub>2</sub> in awake and anesthetized  
dogs. Clin Res 19: 518, 1971.
8. Weiskopf RB, LW Raymond, JW Severinghaus.  
Effects of halothane on canine respiratory responses to hypoxia  
with and without hypercarbia. Anesthesiology 41: 350-360, 1974.
9. Weil JV, RE McCullough, JS Kline, IE Sodal.  
Diminished ventilatory response to hypoxia and hypercapnia after  
morphine in normal man. New Engl J Med 292: 1103-1106, 1975.
10. Hirshman CA, RE McCullough, JV Weil, PJ Cohen.  
Depression of hypoxic ventilatory drive by halothane and  
enflurance. Fed Proc 34: 750, 1975.
11. Hirshman CA, RE McCullough, PJ Cohen, JV Weil.  
Hypoxic ventilatory drive in dogs during thiopental, ketamine,  
or pentobarbital anesthesia. Anesthesiology 43: 628-634, 1975.



12. Gabel RA, RB Weiskopf.  
Ventilatory interaction between hypoxia and  $[H^+]$  at chemoreceptors of man. *J Appl Physiol* 39: 292-296, 1975.
13. Weiskopf RB, RA Gabel.  
Depression of ventilation during hypoxia in man. *J Appl Physiol* 39: 911-915, 1975.
14. Weiskopf RB, RA Gabel, V Fencf.  
Alkaline shift in lumbar and intracranial CSF in man after five days at high altitude. *J Appl Physiol* 41: 93-97, 1976.
15. Snedecor GW, WG Cochran.  
Statistical methods. 6th Ed. Iowa State University Press; Ames, Iowa, 1967.
16. Brunk SF, M Delle.  
Morphine metabolism in man. *Clin Pharmacol Ther* 16: 51-57, 1974.
17. Spector S, ES Vessell.  
Disposition of morphine in man. *Science* 174: 421-422, 1971.
18. Beaver WT, SL Wallenstein, RW Houde, et al.  
A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. *Clin Pharmacol Ther* 7: 740-751, 1966.
19. Berkowitz BA, SH Ngai, JC Yang, et al.  
The disposition of morphine in surgical patients. *Clin Pharmacol Ther* 17: 629-635, 1975.
20. Martin WR.  
Opioid antagonists. *Pharmacol Rev* 19: 463-521, 1967.
21. Jasinski DR, WR Martin, JD Sapira.  
Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. *Clin Pharmacol Ther* 9: 215-222, 1968.
22. Foldes FF, D Duncalf, S Kuwabara.  
The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anesthetized subjects. *Can Anaes Soc J* 16: 151-161, 1969.
23. Jasinski DR, WR Martin, CA Haertzen.  
The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). *J Pharmacol Exp Ther* 17: 420-426, 1967.
24. Palminteri A.  
Clinical appraisal of the narcotic antagonist N-allylnoroxymorphone. *J Amer Vet Med Assoc* 148: 1396-1399, 1966.

25. Chapman RW, TV Santiago, AV Khan, NH Edelman.  
Effect of morphine on the cerebral blood flow responses to  
hypoxia and hypercapnia. Fed Proc 35: 719, 1976.
26. Sorensen SC, JC Cruz.  
Ventilatory response to a single breath of CO<sub>2</sub> in O<sub>2</sub> in normal  
man at sea level and high altitude. J Appl Physiol 27: 186-190,  
1969.



The authors gratefully acknowledge the support of John Szurek  
in automated data acquisition and processing.



# DISCLAIMERS

"The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense."

"In conducting the research described in this report, the investigators adhered to the 'Guide for Laboratory Animal Facilities and Care' as promulgated by the Committee on the Guide for Laboratory Animal Facilities and Care of the Institute of Laboratory Animal Resources, National Academy of Sciences - National Research Council."




Table 1

Dog #	Ventilation ( $\text{L} \cdot \text{min}^{-1}$ , BTPS)			
	Unmedicated	45 Min After Morphine	After Naloxone 3-4 min	30-45 min
BJ	$26.1 \pm 1.8$	$19.7 \pm 1.6^*$	$34.6 \pm 2.0^{*+}$	$22.9 \pm 2.2^o$
JQ	$19.6 \pm 2.0$	$6.9 \pm 0.7^*$	$25.1 \pm 2.5^{*+}$	$12.2 \pm 0.6^{*+o}$
PL	$32.9 \pm 0.9$	$12.1 \pm 1.0^*$	$32.6 \pm 0.8^+$	$26.0 \pm 1.9^{*+o}$

All values are the mean  $\pm$ SE of three trials.

\*indicates  $P < 0.05$  versus unmedicated.

+indicates  $P < 0.05$  versus after morphine.

oindicates  $P < 0.05$  versus 3-4 min after naloxone.



# LEGEND

FIGURE 1: Ventilatory response of one dog to "isocapnic" hypoxia following intravenous administration of morphine, 0.6 mg/kg. Each point represents the mean  $\pm$ SE of three trials, each on a separate day.

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		LEAD INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER M 8/77V (14) USARTEM-M-8/77	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Morphine Depression of Ventilatory Response to Hypoxia, and Reversal by Naloxone, (6)		5. TYPE OF REPORT & PERIOD COVERED
7. AUTHOR(s) (10) Richard B/ Weiskopf, MD, MAJ, MC* George/Volpe, SS Vincent/Forte Nancy/McGavock		6. PERFORMING ORG. REPORT NUMBER
9. PERFORMING ORGANIZATION NAME AND ADDRESS US Army Research Institute of Environmental Medicine Natick, MA 01760		8. CONTRACT OR GRANT NUMBER(s)
11. CONTROLLING OFFICE NAME AND ADDRESS Same as 9. above		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS (16) 3A161101A91C
		12. REPORT DATE (11) Jan 1977
		13. NUMBER OF PAGES 23 (12/24p.)
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		15. SECURITY CLASS. (of this report) Unclassified
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Unlimited		
<div style="border: 1px solid black; padding: 5px; text-align: center;">             DISTRIBUTION STATEMENT A              Approved for public release              Distribution Unlimited           </div>		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES *Dr. Richard B. Weiskopf's Present Address: Letterman Army Institute of Research Presidio of San Francisco, CA 94129		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Regulation of respiration: "isocapnic" hypoxia; ventilation; narcotics: morphine; narcotic antagonist: naloxone		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) Ventilatory response to "isocapnic" hypoxia was measured in awake dogs prior to and following administration of intravenous morphine sulfate, 0.6 mg/kg. Hypoxic ventilation was depressed within 30 minutes, was maximally depressed at one to two hours, and remained depressed for at least six to seven hours following the administration of morphine. Naloxone, 0.4 mg IV, completely reversed the morphine depression of the ventilatory response to hypoxia, but only transiently; 30 to 45 minutes after naloxone reversal, the ventilatory response to hypoxia was again		



significantly depress J. Naloxone alone demonstrated mild agonist properties on the ventilatory response to hypoxia, but the effect varied among the dogs.

1. TYPE OF REPORT & PERIOD COVERED	2. REPORT NUMBER
3. AUTHOR(OR ORIGIN) NAME	4. TITLE
5. PROGRAM ELEMENT PROJECT, TASK & WORK UNIT NUMBERS	6. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)
7. AUTHOR(OR ORIGIN) NAME	8. TITLE
9. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	10. TITLE
11. AUTHOR(OR ORIGIN) NAME	12. TITLE
13. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	14. TITLE
15. AUTHOR(OR ORIGIN) NAME	16. TITLE
17. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	18. TITLE
19. AUTHOR(OR ORIGIN) NAME	20. TITLE
21. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	22. TITLE
23. AUTHOR(OR ORIGIN) NAME	24. TITLE
25. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	26. TITLE
27. AUTHOR(OR ORIGIN) NAME	28. TITLE
29. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	30. TITLE
31. AUTHOR(OR ORIGIN) NAME	32. TITLE
33. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	34. TITLE
35. AUTHOR(OR ORIGIN) NAME	36. TITLE
37. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	38. TITLE
39. AUTHOR(OR ORIGIN) NAME	40. TITLE
41. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	42. TITLE
43. AUTHOR(OR ORIGIN) NAME	44. TITLE
45. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	46. TITLE
47. AUTHOR(OR ORIGIN) NAME	48. TITLE
49. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	50. TITLE
51. AUTHOR(OR ORIGIN) NAME	52. TITLE
53. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	54. TITLE
55. AUTHOR(OR ORIGIN) NAME	56. TITLE
57. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	58. TITLE
59. AUTHOR(OR ORIGIN) NAME	60. TITLE
61. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	62. TITLE
63. AUTHOR(OR ORIGIN) NAME	64. TITLE
65. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	66. TITLE
67. AUTHOR(OR ORIGIN) NAME	68. TITLE
69. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	70. TITLE
71. AUTHOR(OR ORIGIN) NAME	72. TITLE
73. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	74. TITLE
75. AUTHOR(OR ORIGIN) NAME	76. TITLE
77. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	78. TITLE
79. AUTHOR(OR ORIGIN) NAME	80. TITLE
81. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	82. TITLE
83. AUTHOR(OR ORIGIN) NAME	84. TITLE
85. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	86. TITLE
87. AUTHOR(OR ORIGIN) NAME	88. TITLE
89. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	90. TITLE
91. AUTHOR(OR ORIGIN) NAME	92. TITLE
93. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	94. TITLE
95. AUTHOR(OR ORIGIN) NAME	96. TITLE
97. PERFORMING ORGANIZATION NAME(S) & ADDRESS(ES)	98. TITLE
99. AUTHOR(OR ORIGIN) NAME	100. TITLE

unclassified